Thomás Rivelli Giollo is corrected to Thomás Giollo Rivelli
. 2022 Jul 4;16:1421. doi: 10.3332/ecancer.2022.1421
METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
João Glasberg
1,2, Aley Talans
3,4, Thomás Rivelli Giollo
1, Débora Zachello Recchimuzzi
1, João Evangelista Bezerra Neto
1, Rossana Veronica Mendonza Lopez
5, Paulo Marcelo Gehm Hoff
1, Rachel P Riechelmann
2,6
João Glasberg
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
2Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil
Find articles by João Glasberg
Aley Talans
3Department of Medical Radiology, Fleury Group, São Paulo, Brazil
4Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil
Find articles by Aley Talans
Thomás Rivelli Giollo
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
Find articles by Thomás Rivelli Giollo
Débora Zachello Recchimuzzi
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
Find articles by Débora Zachello Recchimuzzi
João Evangelista Bezerra Neto
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
Find articles by João Evangelista Bezerra Neto
Rossana Veronica Mendonza Lopez
5Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
Find articles by Rossana Veronica Mendonza Lopez
Paulo Marcelo Gehm Hoff
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
Find articles by Paulo Marcelo Gehm Hoff
Rachel P Riechelmann
2Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil
6Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil
Find articles by Rachel P Riechelmann
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
2Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil
3Department of Medical Radiology, Fleury Group, São Paulo, Brazil
4Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil
5Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
6Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil
ecancer 16 1369 (2022) https://doi.org/10.3332/ecancer.2022.1369
✉
Correspondence to: Rachel P Riechelmann rachel.riechelmann@accamargo.org.br
Received 2022 Jun 14; Collection date 2022.
Keywords: neuroendocrine tumours, metformin, cancer treatment
© the authors; licensee ecancermedicalscience.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC9458264 PMID: 36158978
This corrects the article on page 1.